[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arrivent Biopharma Inc (AVBP)

Arrivent Biopharma Inc (AVBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,351,141
  • Shares Outstanding, K 46,575
  • Annual Sales, $ 0 K
  • Annual Income, $ -166,310 K
  • EBIT $ -176 M
  • EBITDA $ -179 M
  • 60-Month Beta 1.36
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.81

Options Overview Details

View History
  • Implied Volatility 123.27% (+2.50%)
  • Historical Volatility 61.98%
  • IV Percentile 36%
  • IV Rank 31.80%
  • IV High 311.06% on 02/18/26
  • IV Low 35.69% on 09/05/25
  • Expected Move (DTE 3) 2.59 (8.94%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 126
  • Volume Avg (30-Day) 213
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 11,164
  • Open Int (30-Day) 10,438
  • Expected Range 26.42 to 31.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.04
  • Number of Estimates 3
  • High Estimate $-0.96
  • Low Estimate $-1.09
  • Prior Year $-0.83
  • Growth Rate Est. (year over year) -25.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.40 +5.88%
on 07/21/26
33.99 -14.66%
on 07/20/26
-4.18 (-12.59%)
since 07/17/26
3-Month
25.91 +11.96%
on 05/19/26
35.83 -19.03%
on 06/26/26
+1.14 (+4.09%)
since 05/15/26
52-Week
17.00 +70.65%
on 11/03/25
35.83 -19.03%
on 06/26/26
+9.48 (+48.54%)
since 08/15/25

Most Recent Stories

More News
ArriVent BioPharma Reports Second Quarter 2026 Financial Results

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026 ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to...

AVBP : 29.01 (-1.69%)
ArriVent BioPharma's Runway Tightens Ahead of Mid-Year Data—If It Arrives on Schedule

Barchart Research What to Expect from AVBP Earnings AVBP Generated August 7, 2026 Current Price $30.84 EPS Estimate $$-0.98 Consensus Rating Strong Buy Average Move 4.49% ArriVent BioPharma's Runway Tightens...

AVBP : 29.01 (-1.69%)
ArriVent BioPharma Reports First Quarter 2026 Financial Results

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026 IND clearance of ARR-002, ArriVent’s dual-targeting MUC16/NaPi2b tetravalent...

AVBP : 29.01 (-1.69%)
ArriVent BioPharma's Phase Three Timeline Shift Could Mean Progress or Setback

Barchart Research What to Expect from AVBP Earnings AVBP Generated May 8, 2026 Current Price $29.50 EPS Estimate $$-0.88 Consensus Rating Strong Buy Average Move 4.37% ArriVent BioPharma's Phase Three...

AVBP : 29.01 (-1.69%)
ArriVent BioPharma's Phase Three Timeline Shift Could Mean Progress or Setback

Barchart Research What to Expect from AVBP Earnings AVBP Generated May 8, 2026 Current Price $29.50 EPS Estimate $$-0.88 Consensus Rating Strong Buy Average Move 4.37% ArriVent BioPharma's Phase Three...

AVBP : 29.01 (-1.69%)
ArriVent BioPharma's Phase Three Timeline Shift Could Mean Progress or Setback

Barchart Research What to Expect from AVBP Earnings AVBP Generated May 8, 2026 Current Price $29.50 EPS Estimate $$-0.88 Consensus Rating Strong Buy Average Move 4.37% ArriVent BioPharma's Phase Three...

AVBP : 29.01 (-1.69%)
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approaches Phase 1 initiation expected in the second half of 2026...

AVBP : 29.01 (-1.69%)
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal models Superior anti-tumor activity...

AVBP : 29.01 (-1.69%)
ArriVent BioPharma Reports Full Year 2025 Financial Results

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026 Global pivotal Phase 3 first-line PACC mutant NSCLC study for firmonertinib...

AVBP : 29.01 (-1.69%)
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapy ALPACCA pivotal trial is designed to support...

AVBP : 29.01 (-1.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

ArriVent BioPharma Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent BioPharma Inc. is based in NEWTOWN SQUARE, Pa.

See More

Key Turning Points

3rd Resistance Point 30.64
2nd Resistance Point 30.14
1st Resistance Point 29.57
Last Price 29.01
1st Support Level 28.51
2nd Support Level 28.01
3rd Support Level 27.44

See More

52-Week High 35.83
Last Price 29.01
Fibonacci 61.8% 28.64
Fibonacci 50% 26.42
Fibonacci 38.2% 24.19
52-Week Low 17.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.